Welcome to our dedicated page for Odyssey Health SEC filings (Ticker: ODYY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Odyssey Health Inc. (ODYY) SEC filings page on Stock Titan brings together the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, providing investors with structured access to its official reports and transaction documents. As a Nevada corporation and smaller reporting company whose common stock trades on the OTCQB market, Odyssey uses SEC filings to describe its business model, medical technology portfolio, financing arrangements and material agreements.
Key filings include registration statements such as the Form S-1, where Odyssey outlines its focus on developing and acquiring medical products and health-related technologies, including the CardioMap ae heart monitoring device, the Save A Life choking rescue device and its sub-licensing arrangement for BreastCheck ae, a non-invasive breast abnormality test. The S-1 also details the company’s capital structure, risk factors and agreements with investors like Mast Hill Fund, L.P., including convertible notes and warrants.
Current reports on Form 8-K are particularly important for tracking material events. Recent 8-K filings describe the Master Technology and Sub-license Agreement with NeuRX Health, Inc. for exclusive, worldwide rights to BreastCheck ae; the long-term Maintenance Agreement and related financing facility with Mast Hill Fund, which create a multi-year stream of service fees and convertible debt; and amendments to existing promissory notes with financing partners. Other 8-Ks document the definitive Asset Purchase Agreement and closing with Oragenics, Inc., under which Odyssey sold its neurological drug therapy assets in exchange for cash and Series F Convertible Preferred Stock.
On Stock Titan, these filings are complemented by AI-powered summaries that highlight the core terms of each document, such as maturity dates, conversion features, licensing scopes and asset sale considerations. Users can quickly scan 10-K and 10-Q references incorporated into the S-1, review 8-K event descriptions, and examine details of insider-related financing structures or equity issuances. This makes it easier to understand how Odyssey structures its medical device development activities, manages its balance sheet and discloses significant corporate events through the SEC’s EDGAR system.
Odyssey Health, Inc. reported that on October 9, 2025 it entered into Amendment No. 6 to its promissory note issued on December 13, 2022 with Mast Hill Fund, L.P.
Under this amendment, the maturity date of the promissory note is extended to April 30, 2026, giving the company more time before the debt comes due. The amendment also deletes Section 4.16 titled “Amortization Payments” in its entirety, while all other terms and conditions of the note remain the same.
Odyssey Health, Inc. entered into a new short-term financing arrangement with a private investor. On October 3, 2025, the company received $100,000 under a one-year promissory note effective as of October 1, 2025, bearing interest at 18% per year. This provides near-term cash to the business but at a relatively high interest cost.
As part of this financing, Odyssey issued the investor a warrant to purchase 100,000 shares of its common stock at an exercise price of $0.10 per share
Odyssey Health, Inc. entered into Amendment No. 10 with LGH Investments, LLC, effective as of July 31, 2025, to modify an existing convertible promissory note. Under this amendment, the maturity date of the note is extended to January 31, 2026, giving the company additional time before the debt becomes due, while all other terms and conditions of the note remain unchanged.
The company has filed the form of Amendment No. 10 to the convertible promissory note as an exhibit, making the detailed terms available for review. This update reflects a negotiated change with a financing partner rather than a new financing arrangement.
Odyssey Health, Inc. entered into Amendment No. 10 with LGH Investments, LLC, effective as of July 31, 2025, to modify an existing convertible promissory note. Under this amendment, the maturity date of the note is extended to January 31, 2026, giving the company additional time before the debt becomes due, while all other terms and conditions of the note remain unchanged.
The company has filed the form of Amendment No. 10 to the convertible promissory note as an exhibit, making the detailed terms available for review. This update reflects a negotiated change with a financing partner rather than a new financing arrangement.